EUVIMEDEUVIMED entdecken
Crossref

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy

Pooja Advani, Jonathan Hoyne, Alvaro Moreno-Aspita, Marcia Dubin, Shelly Brock, Caroline Harlow, Saranya Chumsri, Thomas Suter, Joseph L Blackshear

Chemotherapy · 2017 · 62 (6) · 334-338

DOI: 10.1159/000477797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 14.07.2017. Verfasst von Pooja Advani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Berne University Hospital, Bern, Switzerland. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction.

Method

High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients.

Results

Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was 1-2 days for both groups. In the DOX-treated women, hs-TnT showed significant peaks from precycle baseline, increases in precycle 1 to precycle 2 levels, and a cycle 1 to cycle 2 peak and area under the curve (AUC). hs-TnT increased from precycle (1, 4.6 ± 6.3 pg/mL) to a cycle 2 peak of 16.1 ± 15.0 pg/mL (p < 0.002). No increases were seen with the TRA treatment. Transient posttreatment increases in NT-proBNP were seen after both therapies.

Conclusion

DOX was associated with increased pretreatment baseline, peak, and AUC hs-TnT levels. Both DOX and TRA acutely perturb NT-proBNP. Assessment of pre- and posttreatment hs-TnT could be a means of quantifying cumulative myocardial injury in the course of chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAgedAged, 80 and overAntineoplastic AgentsArea Under CurveBreast NeoplasmsDoxorubicinFemaleHumansImmunoassayMiddle AgedNatriuretic Peptide, BrainNeoplasm StagingPeptide FragmentsROC CurveTrastuzumabTroponin T

Stichwörter der Autor:innen

Brain natriuretic peptideBreast cancerDoxorubicinEchocardiographyHigh-sensitivity troponin TTrastuzumab

Substanzen

Antineoplastic AgentsPeptide FragmentsTroponin Tpro-brain natriuretic peptide (1-76)Natriuretic Peptide, BrainDoxorubicinTrastuzumab

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Berne University Hospital, Bern, Switzerland.

Zitieren

APA

Advani, P., Hoyne, J., Moreno-Aspita, A., Dubin, M., Brock, S., Harlow, C., Chumsri, S., Suter, T., & Blackshear, J. L. (2017). High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. Chemotherapy, 62(6), 334-338. https://doi.org/10.1159/000477797

Vancouver

Advani P, Hoyne J, Moreno-Aspita A, Dubin M, Brock S, Harlow C, et al. High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. Chemotherapy. 2017;62(6):334-338. doi:10.1159/000477797

BibTeX
@article{Advani2017,
  author = {Advani, Pooja and Hoyne, Jonathan and Moreno-Aspita, Alvaro and Dubin, Marcia and Brock, Shelly and Harlow, Caroline and Chumsri, Saranya and Suter, Thomas and Blackshear, Joseph L},
  title = {High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy},
  journal = {Chemotherapy},
  year = {2017},
  volume = {62},
  number = {6},
  pages = {334--338},
  doi = {10.1159/000477797}
}
Kostenlos starten →